<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHYLERGONOVINE MALEATE - methylergonovine maleate tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>Methylergonovine Maleate Tablets, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Methylergonovine Maleate is a semi-synthetic ergot alkaloid used for the prevention and control of <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span>.</p>
<p>Methylergonovine Maleate Tablets, USP is available in tablets for oral ingestion containing 0.2 mg methylergonovine maleate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Tablets</h2>
<p class="First"><span class="Italics">Active ingredient: </span>Methylergonovine maleate, USP, 0.2 mg.</p>
<p><span class="Italics">Inactive ingredients: </span>acacia, corn starch, gelatin, lactose monohydrate, methylparaben, microcrystalline cellulose, povidone, propylparaben, stearic acid, and tartaric acid.</p>
<p>Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9, 10-didehydro-<span class="Italics">N</span>-[1-(hydroxymethyl) propyl]-6-methyl-, [8β(<span class="Italics">S</span>)]-, (Z)-2-butenedioate (1:1) (salt). Its structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=047d3ab6-1f93-4080-95c1-f938ce8d5532&amp;name=methylergonovine-01.jpg"><p class="MultiMediaCaptionNotCentered">C<span class="Sub">20</span>H<span class="Sub">25</span>N<span class="Sub">3</span>O<span class="Sub">2</span>•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>                  Mol Wt:  455.51</p></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Methylergonovine maleate acts directly on the smooth muscle of the uterus and increases the tone, rate and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.</p>
<p>Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.</p>
<p>Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of methylergonovine maleate solution was about 25% greater than the tablet. The volume of distribution (Vdss/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (Tmax about 3 hours) of methylergonovine maleate tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For routine management after delivery of the placenta; postpartum atony and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>; toxemia; pregnancy; and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>. If I.V administration is considered essential as a lifesaving measure, methylergonovine maleate should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<p class="First">Caution should be exercised in the presence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, obliterative vascular disease, hepatic or renal involvement. Also use with caution during the second stage of labor. The necessity for manual removal of a <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span> should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors)</h3>
<p class="First">There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. Although there have been no reports of such interactions with Methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
<p>Caution should be exercised when Methylergonovine maleate is used concurrently with other vasoconstrictors or ergot alkaloids.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies have been performed in animals to evaluate carcinogenic potential. The effect of the drug on mutagenesis or fertility has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Category C</h3>
<p class="First">Animal reproductive studies have not been conducted with methylergonovine maleate. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of methylergonovine maleate is contraindicated during pregnancy because of its uterotonic effects. (See<a href="#IU"> INDICATIONS AND USAGE</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The uterotonic effect of methylergonovine maleate is utilized after delivery to assist involution and decrease <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, shortening the third stage of labor.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">Methylergonovine maleate may be administered orally for a maximum of 1 week postpartum to control <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>. Recommended dosage is 1 tablet (0.2 mg) 3 or 4 times daily. At this dosage level a small quantity of drug appears in mothers' milk. Caution should be exercised when methylergonovine maleate is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>GERIATRIC USE</h2>
<p class="First">Clinical studies of methylergonovine maleate did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger  patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reaction is <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> associated in several cases with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has also been reported. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have occurred occasionally. Rarely observed reactions have included: <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, transient <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>, <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arterial spasm</span> (coronary and peripheral), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and foul taste.1</p>
<p>There have been rare isolated reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, without a proven causal relationship to the drug product.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Methylergonovine maleate has not been associated with drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of either a physical or psychological nature.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the extremities, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, in severe cases followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Because reports of overdosage with Methylergonovine maleate are infrequent, the lethal dose in humans has not been established. The oral LD50 (in mg/kg) for the mouse is 187, the rat is 93, and the rabbit 4.5.2 Several cases of accidental methylergonovine Maleate injection in newborn infants have been reported, and in such cases 0.2 mg represents an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of great magnitude. However, recovery occurred in all but in one case following a period of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> with jerking movements, and, in one case, a single <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>. Also, several children 1-3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clamminess</span> as her only symptoms. Treatment of acute overdosage is symptomatic and includes the usual procedures of:</p>
<ol class="Arabic">
<li>removal of offending drug by inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, gastric lavage, catharsis, and supportive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</li>
<li>maintenance of adequate pulmonary ventilation, especially if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> develop.</li>
<li>correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with pressor drugs as needed.</li>
<li>control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> with standard anticonvulsant agents.</li>
<li>control of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> with warmth to the extremities if needed.3</li>
</ol>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Intramuscularly</h2>
<p class="First">1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Intravenously</h2>
<p class="First">Dosage same as intramuscular. (See<a href="#WARNINGS"> WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Orally</h2>
<p class="First">One tablet, 0.2 mg, 3 to 4 times daily in the puerperium for a maximum of 1 week.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">White, round, biconvex compressed tablets debossed with "N" on one side and "01" on the other side. Available in bottles of 28 and 100 tablets.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>STORE AND DISPENSE</h2>
<p class="First">Tablets: Store below 25°C (77°F); in tight, light-resistant container.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Information on Adverse Reactions supplied by Medical Services Department, Novartis Pharmaceuticals, E. Hanover, N.J., based on computerized clinical reports.</li>
<li>Berde, B. and Schild, H.O.:<span class="Italics"> Ergot Alkaloids and Related Compounds, </span>Springer-Verlag, New York, 1978, p. 810.</li>
<li>Treatment of Acute Overdosage. Novartis Consumer Health, Inc. Rx Products. Novartis, Medical Services Department.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured by:<br>Novel Laboratories, Inc.<br>Somerset, NJ 08873</p>
<p>GIN-140-01<br>Rev. 04/2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.2 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC 63704-006-01</span></p>
<p><span class="Bold">Methylergonovine<br>Maleate<br>Tablets, USP</span></p>
<p><span class="Bold">0.2 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold"></span><span class="Italics"><br></span></p>
<div class="Figure"><img alt="43063329 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=047d3ab6-1f93-4080-95c1-f938ce8d5532&amp;name=43063329.jpg"></div>
<br>PDRx Labels<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLERGONOVINE MALEATE 		
					</strong><br><span class="contentTableReg">methylergonovine maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-329(NDC:63704-006)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methylergonovine maleate</strong> (methylergonovine) </td>
<td class="formItem">methylergonovine maleate</td>
<td class="formItem">0.2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acacia</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">N;01</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-329-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:43063-329-03</td>
<td class="formItem">3  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:43063-329-04</td>
<td class="formItem">4  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:43063-329-06</td>
<td class="formItem">6  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:43063-329-08</td>
<td class="formItem">8  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:43063-329-09</td>
<td class="formItem">9  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:43063-329-10</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">8</th>
<td class="formItem">NDC:43063-329-12</td>
<td class="formItem">12  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">9</th>
<td class="formItem">NDC:43063-329-20</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091577</td>
<td class="formItem">08/01/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dd491177-c103-46e3-ae01-b01819338631</div>
<div>Set id: 047d3ab6-1f93-4080-95c1-f938ce8d5532</div>
<div>Version: 1</div>
<div>Effective Time: 20110524</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
